Superior Therapeutic Efficacy of Alphavirus-Mediated Immunization against Human Papilloma Virus Type 16 Antigens in a Murine Tumour Model: Effects of the Route of Immunization
Authors:
- 1 July 2004
- journal article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 9 (5) , 733-742
Abstract
In our efforts to develop a strong, effective immune response against cervical carcinoma and premalignant disease, we study the use of recombinant Semliki Forest virus (SFV) encoding the oncoproteins E6 and E7 from high-risk human papilloma viruses (HPVs). Optimal immunization conditions are required for immunotherapeutic treatment of cervical cancer as it has been postulated that cervical cancer patients are immune-suppressed and/or immunologically tolerant for HPV. We previously generated an optimized construct encoding a fusion protein of HPV16 E6 and E7 and a translational enhancer (enhE6,7). Immunization of mice with SFV-enhE6,7 was shown to induce cytoxic T cell (CTL) responses and resulted in the eradication of established tumours. We now demonstrate, using HPV16-specific MHC class I tetramers, that high pCTL frequencies can be induced. However, this induction is strongly influenced by the route of immunization applied. Whilst in bulk CTL assays, requiring in vitro restimulation, CTL activity can be observed upon sc, ip, iv and im immunization, detectable pCTL frequencies, without in vitro restimulation, are only induced upon im and iv immunization. The route of immunization also strongly influences the dose of viral vector needed to induce CTLs and tumour therapy. As few as 5x10 4 SFV-enhE6,7, primed and boosted iv, are needed to eradicate tumours in six out of seven mice treated. Furthermore, exponentially growing tumours of approximately 500 mm 3 in size were seen to completely resolve and even tumours as large as 1500 mm 3 decreased to one-third of their size. Apart from this potency, SFV vectors can safely be used for the expression of oncoproteins such as E6 and E7, since the viral RNA is not integrated in the host genome. Thus SFV-enhE6,7 meets with the criteria that a vaccine against cervical cancer should be safe and induce a very strong, long-lasting CTL response, strong enough to eradicate existing tumours.Keywords
This publication has 22 references indexed in Scilit:
- Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-primingVaccine, 2004
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Alphavirus vectors and vaccinationReviews in Medical Virology, 2002
- Papillomaviruses and cancer: from basic studies to clinical applicationNature Reviews Cancer, 2002
- Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22–Antigen FusionHuman Gene Therapy, 2002
- Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7Gene Therapy, 2002
- Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aortaGene Therapy, 2002
- Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccinesGene Therapy, 2001
- Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell responseGene Therapy, 2001
- Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSFGene Therapy, 2001